Boundless Bio, Inc. (BOLD)

9,10 -0,80 (-8,08%) Börsenschluss: 04:00PM EDT

Boundless Bio, Inc.

9880 Campus Point Drive
Suite 120
San Diego, CA 92121
United States
(858) 766-9912
https://boundlessbio.com

Sektor(en): Healthcare
Branche: Biotechnology
Vollzeitmitarbeiter: 72

Leitende Angestellte

Name	Titel	Zahlen	Ausgeübt	Geburtsjahr
Dr. Jonathan E. Lim M.D.	Co-Founder & Independent Chairman	N/A	N/A	1972
Mr. Zachary Hornby	CEO, President & Director	721,05k	N/A	1979
Dr. Christian Hassig Ph.D.	Chief Scientific Officer	563,55k	N/A	1973
Dr. Klaus W. Wagner M.D., Ph.D.	Chief Medical Officer	633,08k	N/A	1973
Ms. Jamilu E. Rubin	Chief Financial Officer	N/A	N/A	1964
Ms. Jessica Oien J.D.	Chief Legal Officer & Corporate Secretary	N/A	N/A	1972
Mr. Neil Abdollahian M.B.A., M.S.	Chief Business Officer	N/A	N/A	1973
Mr. Anthony Pinkerton Ph.D.	Senior Vice President of Drug Discovery	N/A	N/A	N/A
Ms. Meredith Wesley	Senior Vice President of Talent & Culture	N/A	N/A	N/A
Dr. Shailaja Kasibhatla Ph.D.	Senior Vice President of Discovery & Translational Development	N/A	N/A	N/A

Die Beträge haben den Stand 31. Dezember 2023 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in USD.

Beschreibung

Boundless Bio, Inc., a clinical-stage oncology company, develops cancer therapeutics to address the unmet need of patients with oncogene amplified tumors by targeting extrachromosomal DNA. Its lead product candidate is BBI-355, an oral inhibitor of checkpoint kinase 1 that is in Phase 1/2 clinical trial in patients with oncogene amplified cancers. The company is also developing BBI-825, an oral inhibitor of ribonucleotide reductase, which is in Phase 1/2 clinical trial in cancer patients with resistance gene amplifications; and ecDTx 3 program targeting a kinesin involved with the cellular mechanism for segregation of ecDNA. Boundless Bio, Inc. was formerly known as Pretzel Therapeutics, Inc. and changed its name to Boundless Bio, Inc. in July 2019. The company was incorporated in 2018 and is headquartered in San Diego, California.

Corporate Governance

Boundless Bio, Inc.s ISS Governance QualityScore, Stand N/A, lautet N/A. Die grundlegenden Scores sind Audit: N/A, Vorstand: N/A, Shareholderrechte: N/A, Kompensation: N/A.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.